Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modern Molecular Taxonomy01:29

Modern Molecular Taxonomy

Advancements in molecular biology have revolutionized the identification and characterization of bacteria, with multiple methods leveraging DNA sequencing for enhanced precision. As sequencing technologies improve and costs decline, these approaches are increasingly used in clinical, environmental, and evolutionary studies.Multilocus Sequence Typing (MLST) examines several housekeeping genes, essential chromosomal genes encoding cellular functions, to distinguish strains. Approximately...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erdafitinib in Patients With Advanced Solid Tumors With <i>FGFR</i> Alterations (RAGNAR): Results of Tumor-Specific Analyses and Secondary Cohorts.

JCO precision oncology·2026
Same author

The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers.

Cancer research·2026
Same author

Spatial transcriptomic atlas of aggressive osteosarcomas reveals shared immune landscape and targetable surface markers.

Nature communications·2026
Same author

Frequency and Prognostic Significance of Genetic Abnormalities in a Subgroup of Patients With Intermediate-Risk Neuroblastoma: A SIOPEN Study.

JCO precision oncology·2026
Same author

Economic evaluation of adjuvant chemotherapy for non-metastatic sarcoma using the real-world data from the French nationwide DEEPSARC study.

Journal of medical economics·2026
Same author

Clinicopathological, Molecular, and DNA Methylation Analysis of Ossifying Fibromyxoid Tumors Delineates the ZC3H7B::BCOR Subset as a Distinct Entity.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026

Related Experiment Video

Updated: Jun 9, 2026

Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

6.8K

Sequential genomic analysis using a multisample/multiplatform approach to better define rhabdomyosarcoma progression

Henry de Traux de Wardin1,2, Josephine K Dermawan1, Marie-Sophie Merlin3

  • 1Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

NPJ Precision Oncology
|September 20, 2023
PubMed
Summary

Genomic analysis of rhabdomyosarcoma (RMS) reveals stable genomes in fusion-positive RMS and acquired mutations in fusion-negative RMS. Liquid biopsy effectively detects tumor progression and aids in monitoring treatment response.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.2K

Related Experiment Videos

Last Updated: Jun 9, 2026

Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

6.8K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.2K

Area of Science:

  • Oncology
  • Genomics
  • Molecular Biology

Background:

  • The genomic landscape of rhabdomyosarcoma (RMS) progression from primary to relapsed disease remains incompletely characterized.
  • Understanding genomic alterations is crucial for developing effective therapeutic strategies and monitoring treatment response in RMS.

Purpose of the Study:

  • To evaluate the sensitivity of various next-generation sequencing (NGS) platforms for genomic profiling of RMS.
  • To assess the feasibility of using liquid biopsy for monitoring treatment response and relapse in RMS patients.
  • To investigate genomic differences between primary and relapsed fusion-positive (FP-RMS) and fusion-negative (FN-RMS) rhabdomyosarcoma.

Main Methods:

  • Paired primary/relapsed tumor samples from 35 RMS patients (18 FP-RMS, 17 FN-RMS) were analyzed using targeted DNA and whole exome sequencing (WES).
  • Circulating tumor DNA (ctDNA) from 10 patients was analyzed using a targeted 36-gene RMS panel and shallow whole-genome sequencing (WGS) for copy number variation.
  • NGS platforms were compared for sensitivity in detecting single-nucleotide variations, fusions, and copy number alterations.

Main Results:

  • Fusion-positive RMS exhibited genomic stability at relapse, with common secondary alterations (CDKN2A/B, MYCN, CDK4) impacting survival.
  • Fusion-negative RMS acquired a higher number of new alterations, notably SMARCA2 missense mutations, at relapse.
  • ctDNA analysis successfully detected pathognomonic variants at diagnosis in all RMS patients and confirmed relapse in 86% of FP-RMS and 100% of FN-RMS.
  • Increased fusion reads in ctDNA correlated with higher disease burden and predicted fatal outcomes.

Conclusions:

  • Genomic profiling of paired primary and relapsed RMS samples reveals distinct progression patterns between FP-RMS and FN-RMS.
  • Liquid biopsy using ctDNA is a feasible and sensitive approach for detecting RMS alterations and monitoring disease progression and relapse.
  • These findings provide a strong rationale for incorporating liquid biopsy into future clinical trials for RMS treatment monitoring.